Home > Healthcare > Pharmaceuticals > Drug Delivery > Nasal Drug Delivery Technology Market

Nasal Drug Delivery Technology Market Trends

Report ID: GMI12155
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

Nasal Drug Delivery Technology Market Trends

Nasal delivery is branching out into diverse areas such as hormone treatments, insulin delivery, and therapies targeting central nervous system disorders. This broadening not only fuels market growth but also widens the spectrum of nasal drug delivery applications. With ongoing research, these systems could unveil novel solutions for intricate health challenges, potentially elevating patient outcomes and enhancing quality of life.
Moreover, merging nasal drug delivery with nanotechnology facilitates the efficient transport of high molecular weight drugs, peptides, and proteins. Utilizing nanocarriers like liposomes and chitosan-based nanoparticles boosts drug stability and absorption via the nasal mucosa.
In addition, technological advancements in devices have revolutionized nasal drug delivery. Innovations such as pressurized metered-dose inhalers, dry powder inhalers, and unit-dose devices have ushered in heightened dose accuracy, superior control, and enhanced patient compliance, rendering nasal drug delivery not only more effective but also more user-friendly.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of nasal drug delivery technology reached USD 71.9 billion in 2023 and is set to grow at a 6.8% CAGR from 2024 to 2032, driven by increased demand for non-invasive drug delivery systems.

The non-pressurized containers segment held an 82.2% market share in 2023, as they offer improved ease of use for patients, particularly in self-administration scenarios.

The U.S. market was valued at USD 30 billion in 2023 and is expected to expand at a CAGR of 6.9% over the forecast period, propelled by the high prevalence of allergic conditions and asthma.

Key players in the industry include Aegis Therapeutics, AptarGroup, Boehringer Ingelheim, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline, Horizon Therapeutics, Johnson & Johnson, Merck, Nasal Technologies.